| __timestamp | ImmunityBio, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 79383000 |
| Thursday, January 1, 2015 | 226206000 | 108402000 |
| Friday, January 1, 2016 | 94391000 | 46928000 |
| Sunday, January 1, 2017 | 53821000 | 74959000 |
| Monday, January 1, 2018 | 35463000 | 79716000 |
| Tuesday, January 1, 2019 | 46456000 | 74669000 |
| Wednesday, January 1, 2020 | 71318000 | 59040000 |
| Friday, January 1, 2021 | 135256000 | 77417000 |
| Saturday, January 1, 2022 | 102708000 | 91473000 |
| Sunday, January 1, 2023 | 129620000 | 94314000 |
In pursuit of knowledge
In the ever-evolving biotech industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ImmunityBio, Inc. and MannKind Corporation from 2014 to 2023. ImmunityBio's SG&A expenses surged by over 2,900% from 2014 to 2023, peaking in 2015 with a notable 2,262% increase. Meanwhile, MannKind's expenses remained relatively stable, with a modest 19% increase over the same period. The data reveals ImmunityBio's aggressive expansion strategy, while MannKind maintained a more conservative approach. These trends highlight the contrasting financial strategies of two key players in the biotech sector, offering insights into their operational priorities and market positioning. As the industry continues to grow, monitoring such financial metrics will be essential for investors and stakeholders.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared